Companion Diagnostics in Drug Development

  • Companion Diagnostics as a real differentiator For Drug Development in Oncology, CNS, and Other Therapeutic Areas Developing Targeted Drugs

    • Targeted Biologics Will Have An Accompanying Diagnostic Test
    • Invest early to Identify targeted patient Population
    • Identify Responders Vs. Non Responders
    • Drive Compounds Quicker to Decision
    • Improve Success rate of Phase III Trials
    • Prescreen patients to determine the optimal Choice of Drugs

Investigating Genetic Marker in Neurodegenerative Diseases - Companion Diagnosis in CNS

Customized Biomarker Developments For Targeted Biologics in Development For Neurodegenerative Disorders Including Alzheimer's Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Autism and other CNS Disorders.

  • Enable Early Proof of Mechanism and Decision Making

    Re-evaluate compounds that failed in clinical trials but demonstrated efficacy in a subset of patients.

    Develop Diagnostics Tests for pre-screening patients to determine the optimal choice of drugs.

  • GDI Staff has extensive Experience In Designing CNS and Oncology Clinical Trials and Biomarker Development for Targeted Therapies

    GDI can Partner with Pharmaceutical companies to develop Customized Genetic Markers for Drugs in Development

    These marker can also be utilized to screen patients who will be responsive to the targeted therapy

    GDI can offer Liquid Biopsy for Diagnosis, Prognosis and Drug Resistance, both De-novo and Acquired